What Happened To Ranbaxy Brothers? A Look At Their Rise And Fall

The Ranbaxy brothers, Malvinder and Shivinder Singh, were sentenced to six months in prison by the Supreme Court. This came fourteen years after selling their family-owned pharmaceutical company, Ranbaxy, to Japan’s Daiichi Sankyo for a significant $4.6 billion.

The brothers were found guilty of financial irregularities related to their management of Religare Enterprises, a financial services company they acquired after selling Ranbaxy. The Supreme Court determined they had misused funds belonging to Religare, a charge they vehemently denied.

This judgment concluded a long legal battle that began in 2017 when the Delhi High Court initially ordered their arrest for financial misconduct. While the brothers appealed this decision, they were ultimately held accountable for their actions.

Their sentencing is a stark reminder of the legal consequences associated with financial impropriety, particularly when entrusted with managing large corporations. It also highlights the responsibility of corporate leaders to act ethically and with transparency. The case serves as a cautionary tale for all businesses, emphasizing the importance of robust corporate governance and accountability.